EC Pulmonology and Respiratory Medicine

Editorial Volume 12 Issue 5 - 2023

The Morphology of Pulmonary Involvement in COVID-19 Infection Stimulates and Requires a Differentiating Terminology in Inflammatory Lung Diseases

Peter von Wichert*

Professor of Medicine, Philipps University, Marburg, Germany

*Corresponding Author: Peter von Wichert, Professor of Medicine, Philipps University, Marburg, Germany. Address: Eppendorfer Landstr. 14, D-20249 Hamburg, Germany - mail vonwichert@t-online.de
Received: June 21, 2023; Published:June 27, 2023



The paper shows using the example of Covid-19-infection, that it is necessary to define pulmonary infections and alterations on the basis of morphology. Using the term pneumonia only is misleading and may be harmful for patients with lung parenchyma infections.

Keywords: Pneumonia; Covid-19; Lung Parenchyma Infection; Alveolitis

  1. Menter T., et al. “Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction”. Histopathology 2 (2020): 198-209.
  2. Tabary M., et al. “Pathologic features of COVID-19: A concise review”. Pathology - Research and Practice 9 (2020): 153097.
  3. Arossi AV and Farver C. “The pulmonary pathology of COVID-19”. Cleveland Clinic Journal of Medicine 6 (2020).
  4. Bösmüller H., et al. “The pulmonary pathology of COVID-19”. Virchows Archiv 478 (2021): 137-150.
  5. Abul Bashar MMKI and Kahn MAAK. “Lung transcriptome of a COVID-19 patient and systems biology predictions suggest impaired surfactant production with may be druggable by surfactant therapy”. Scientific Reports 10 (2020): 19395.
  6. Carcaterra M and Caruso C. “Alveolar type II as the main target of SARS.CoV-2 virus and COVID-19 Development via NF-Kb pathway deregulation: A physio-pathological Theory”. Medical Hypotheses 146 (2021): 110412.
  7. Lewis JF and Jobe AH. “Surfactant and the adult respiratory distress syndrome”. American Review of Respiratory Disease 1 (1993): 218-233.
  8. Bollag WB and Gonzales JN. “Phosphatidylglycerol and surfactant: a potential treatment for COVID-19”. Medical Hypotheses 144 (2020): 110277.
  9. Piva S., et al. “Surfactant therapy for COVID-19 related ARDS. A retrospective case-control pilot study”. Respiratory Research 1 (2021): 20.
  10. Habashi NM., et al. “Functional pathophysiology of SARS-CoV-2 induced acute lung injury and clinical implications”. Journal of Applied Physiology 3 (2021): 877-891.
  11. Ackermann M., et al. “Pulmonary vascular endothelialitis, thrombosis and angiogenesis in Covid-19”. New England Journal of Medicine 2 (2020): 120-128.
  12. Gattinoni L., et al. “COVID-19 does not lead to a typical acute respiratory distress syndrome”. American Journal of Respiratory and Critical Care Medicine 10 (2020): 1299-1300.
  13. Guyton AC and Moffat DS. “Role of surface tension and surfactant in the transepithelial movement of fluid and in the development of pulmonary edema”. In: Clinical importance of surfactant defects. Ed: P. v. Wichert, Karger Basel (1981).
  14. Perier F., et al. “Effect of positive end-expiratory pressure and proning on ventilation and perfusion in COVID-19 acute respiratory distress syndrome”. American Journal of Respiratory and Critical Care Medicine 12 (2020): 1713-1717.
  15. Dail DH and Hammar SP. “Pulmonary Pathology”. Springer, New York (1994).

Peter von Wichert. "The Morphology of Pulmonary Involvement in COVID-19 Infection Stimulates and Requires a Differentiating Terminology in Inflammatory Lung Diseases". EC Pulmonology and Respiratory Medicine  12.5 (2023): 69-72.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net